早期反应对预测接受选择性内放射治疗的肝细胞癌患者生存的预后价值
该回顾性分析纳入102例2018至2020年接受选择性内放射治疗(SIRT)的肝细胞癌(HCC)患者,于治疗后3个月用RECIST、mRECIST和LR-TRA评估肿瘤反应。中位随访32.0个月后,RECIST、mRECIST和LR-TRA评估的早期反应均未预测总生存(OS)或无进展生存(PFS),而疾病进展和肝功能指标是OS的预后因素。
要点
- SIRT后3个月RECIST、mRECIST和LR-TRA评估的早期反应均未预测OS或PFS。
- RECIST和mRECIST评估的疾病进展及胆红素、凝血酶原时间是OS的预测因素。
- 在BCLC-C期为主的晚期HCC人群,早期影像学反应标准预测生存的价值有限。
核心结论
- 在晚期HCC人群中,SIRT后3个月RECIST、mRECIST和LR-TRA评估的早期反应未预测OS或PFS;早期疾病进展和肝功能指标是OS的预后因素。
研究设计与样本
- 回顾性分析纳入2018至2020年接受SIRT的102例HCC患者,于SIRT后3个月评估RECIST、mRECIST和LR-TRA,采用Kaplan-Meier分析和Cox比例风险模型评估OS和PFS。
诊断标准与关键数值
- RECIST 1.1评估的早期反应预测OS的HR为1.66(p=0.30),未达统计学显著。
- mRECIST评估的早期反应预测OS的HR为1.40(p=0.215),未达统计学显著。
- LR-TRA评估的早期反应预测OS的HR为0.67(p=0.30),未达统计学显著。
- RECIST评估的疾病进展预测OS的HR为2.55(p<0.001)。
- mRECIST评估的疾病进展预测OS的HR为2.53(p<0.001);胆红素HR为1.03(p<0.001),凝血酶原时间HR为0.98(p=0.005)。
临床应用与阅片要点
- 原文结论提示,SIRT后3个月用RECIST、mRECIST和LR-TRA评估的早期反应不宜单独用于预测该晚期HCC人群的生存。
- 原文结论显示,早期疾病进展和肝功能指标(胆红素、凝血酶原时间)与OS相关,可作为预后参考因素。
局限性
- 原文为回顾性分析。
- 原文指出早期影像学标准在预测晚期HCC接受SIRT后生存结局方面存在局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study evaluates the prognostic value of tumor response on CT at 3 months, assessed by Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), and Liver Imaging Reporting and Data System Treatment Response Algorithm (LR-TRA) in patients with hepatocellular carcinoma (HCC) treated with selective internal radiation therapy (SIRT).
MATERIALS AND METHODS: A retrospective analysis was conducted on 102 HCC patients treated with SIRT between 2018 and 2020. RECIST, mRECIST, and LR-TRA were assessed at 3 months post-SIRT. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier analysis and Cox proportional-hazards models.
RESULTS: The median age was 71 years, and most patients (90%) had advanced-stage tumors (Barcelona Clinic Liver Cancer-C). After a median follow-up of 32.0 months (95% CI: 16.8-60.9), 60/102 patients died (59%), and 90/102 patients showed tumor progression (88%). Median OS was 20.4 months (95% CI: 15.4-33.0), and median PFS was 14.5 months (95% CI: 6.5-24.5); 1-year OS and PFS rates were 65.6% and 50.7%. Multivariable analysis revealed that early response according to RECIST 1.1 (HR 1.66, p = 0.30), mRECIST (HR 1.40, p = 0.215), and LR-TRA (HR 0.67, p = 0.30) were not predictors of OS. Disease progression evaluated by RECIST (HR 2.55, p < 0.001) and mRECIST (HR 2.53, p < 0.001), bilirubin levels (HR 1.03, p < 0.001), and prothrombin time (HR 0.98, p = 0.005) were predictors of OS. For PFS, neither RECIST nor mRECIST response, disease progression, nor LR-TRA viability were predictors.
CONCLUSION: In this advanced-stage HCC population, early response assessed by RECIST, mRECIST, and LR-TRA criteria did not predict OS or PFS after SIRT. However, early disease progression and liver function indicators were prognostic factors for OS.
KEY POINTS: QuestionHow well does early tumor response, assessed at 3 months post-selective internal radiation therapy (SIRT), predict survival in advanced hepatocellular carcinoma (HCC) patients? Findings Early response, assessed by RECIST, mRECIST, and LR-TRA, did not predict overall or progression-free survival; disease progression and liver function indicators were significant predictors. Clinical relevance This study highlights the limitations of early imaging criteria in predicting survival outcomes in advanced HCC post-SIRT, suggesting the need for alternative or complementary prognostic indicators to guide treatment decisions.
引用
- Dupuis M, Dupont A, Pizza S, et al. Prognostic value of early response in predicting survival in hepatocellular carcinoma patients treated with selective internal radiation therapy. Eur Radiol. 2024. PMID: 39702632. doi:10.1007/s00330-024-11253-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。